Publication of 2023 financial results and operating update
Financial highlights include successful public rights offering and the subsequent 2024 buyback of all convertible bonds,…
Financial highlights include successful public rights offering and the subsequent 2024 buyback of all convertible bonds,…
XORTX Therapeutics Inc. („XORTX“ oder das „Unternehmen“) (NASDAQ: XRTX | TSX-V: XRTX | Frankfurt: ANUA WKN: A3UNZ), ein…
479,624 Warrants Z were exercised resulting in the issuance of 599,530 new ordinary shares Outstanding 3,326,104 War…
Guaranteed portion of the transaction will extend cash runway past regulatory milestones in Q1-2024 The financial visibi…
Survival data from NOX-A12 GLORIA Phase 1/2 trial in brain cancer continue to improve and have already surpassed all rel…
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…
Direct MagnetOs sales grew to CHF 20.4 million in the first nine months of 2023, climbing from CHF 8.1 million in th…
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…
Lonza to acquire Synaffix B.V., an innovative biotech company focused on antibody-drug conjugates (ADCs) Acquisition w…
NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by tar…